Management of Progressive Disease with Pelvic Invasion
Assessment and Immediate Intervention
- The European Society for Medical Oncology recommends immediate multidisciplinary evaluation, including urology or gynecology consultation, for patients with progressive disease and new urinary symptoms from presacral disease progression, with a switch to second-line systemic therapy 1, 2
- Patients with progressive disease on first-line FOLFIRI-panitumumab should be assessed for interval increase in hepatic metastases and new hypermetabolic presacral soft tissue mass causing urinary urgency 1, 2
Systemic Therapy Change
- The American Society of Clinical Oncology recommends switching to FOLFOX (oxaliplatin-based chemotherapy) plus bevacizumab as the preferred second-line option for patients with progressive disease on first-line FOLFIRI-panitumumab 1, 2
- Bevacizumab (anti-VEGF) should replace panitumumab (anti-EGFR) in second-line therapy, regardless of prior bevacizumab use, RAS status, or primary tumor location 1, 2
Molecular Testing Considerations
- Patients with BRAF V600E mutation should be considered for encorafenib-cetuximab as the preferred second-line option, with superior outcomes (Level I, Grade A evidence) 1, 2
- Patients with dMMR/MSI-H status should be considered for ipilimumab-nivolumab, with Level III, Grade B evidence in the second-line setting 2
Monitoring and Reassessment
- Patients should be reevaluated every 2 months with imaging during second-line therapy, and monitored closely for urinary symptoms and oxaliplatin-related neuropathy 1, 4